We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Journal Scan / Research · December 02, 2019

Nivolumab + Alternatively Scheduled Ipilimumab in First-Line Treatment of Advanced or Metastatic RCC

BMC Cancer

 

Additional Info

BMC Cancer
PRISM Protocol: A Randomised Phase II Trial of Nivolumab in Combination With Alternatively Scheduled Ipilimumab in First-Line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma
BMC Cancer 2019 Nov 14;[EPub Ahead of Print], HL Buckley, FJ Collinson, G Ainsworth, H Poad, L Flanagan, E Katona, HC Howard, G Murden, RE Banks, J Brown, G Velikova, T Waddell, K Fife, PD Nathan, J Larkin, T Powles, SR Brown, NS Vasudev

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading